Evidence map›Paper›PMID 23596057›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2013

Pivotal role of mouse mast cell protease 4 in the conversion and pressor properties of Big-endothelin-1.

Martin Houde, Marc-David Jamain, Julie Labonté, Louisane Desbiens, Gunnar Pejler, Michael Gurish, Shinji Takai, Pedro D'Orléans-Juste

Open access · greenAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Sheltered in Stromal Tissue Cells,Pathogens (Basel, Switzerland) · 2022
    Article
  3. Mast Cell Chymase and Kidney Disease.International journal of molecular sciences · 2020
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Endothelin.Pharmacological reviews · 2016
    Review
  10. Article
  11. Mast cell secretory granules: armed for battle.Nature reviews. Immunology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Martin HoudeDepartment of Pharmacology, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Marc-David Jamain
Julie Labonté
Louisane Desbiens
Gunnar Pejler
Michael Gurish
Shinji Takai
Pedro D'Orléans-Juste
Harvard University · USBrigham and Women's Hospital · USSwedish University of Agricultural Sciences · SEUniversité de Sherbrooke · CA

Funding

THE ROLE OF NATURAL ANTIBODY IN REPERFUSION INJURYP50GM052585 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI MOORE, FRANCIS D · 1995 to 2011
$17.1M
Mechanisms of Pulmonary Mast Cell Recruitment and MaturationR01AI083516 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI GURISH, MICHAEL FAGERSTEN · 2009 to 2012
$1.6M
CIHR MOP-57883NIAID NIH HHS R01 AI083516NIAID NIH HHS R01-AI083516NIGMS NIH HHS GM 052585-15NIGMS NIH HHS P50 GM052585
6 · The paper itself

Abstract

The serine protease chymase has been reported to generate intracardiac angiotensin-II (Ang-II) from Ang-I as well as an intermediate precursor of endothelin-1 (ET-1), ET-1 (1-31) from Big-ET-1. Although humans possess only one chymase, several murine isoforms are documented, each with its own specific catalytic activity. Among these, mouse mast cell protease 4 (mMCP-4) is the isoform most similar to the human chymase for its activity. The aim of this study was to characterize the capacity of mMCP-4 to convert Big-ET-1 into its bioactive metabolite, ET-1, in vitro and in vivo in the mouse model. Basal mean arterial pressure did not differ between wild-type (WT) and mMCP-4(-/-) mice. Systemic administration of Big-ET-1 triggered pressor responses and increased blood levels of immunoreactive (IR) ET-1 (1-31) and ET-1 that were reduced by more than 50% in mMCP-4 knockout (-/-) mice compared with WT controls. Residual responses to Big-ET-1 in mMCP-4(-/-) mice were insensitive to the enkephalinase/neutral endopeptidase inhibitor thiorphan and the specific chymase inhibitor TY-51469 {2-[4-(5-fluoro-3-methylbenzo[b]thiophen-2-yl)sulfonamido-3-methanesulfonylphenyl]thiazole-4-carboxylic acid}. Soluble fractions from the lungs, left cardiac ventricle, aorta, and kidneys of WT but not mMCP-4(-/-) mice generated ET-1 (1-31) from exogenous Big-ET-1 in a TY-51469-sensitive fashion as detected by high-performance liquid chromatography/ matrix-assisted laser desorption/ionization-mass spectrometry. Finally, pulmonary endogenous levels of IR-ET-1 were reduced by more than 40% in tissues derived from mMCP-4(-/-) mice compared with WT mice. Our results show that mMCP-4 plays a pivotal role in the dynamic conversion of systemic Big-ET-1 to ET-1 in the mouse model.

Indexed as

AnimalsAortaCarboxypeptidases ADrug ResistanceEndothelin-1Gene Expression Regulation, EnzymologicHeart VentriclesHemodynamicsIsoenzymesMaleMiceMice, Inbred C57BLMice, KnockoutOrgan SpecificityPeptide FragmentsProtein Processing, Post-TranslationalCarboxypeptidases AEndothelin-1endothelin-1 (1-31)Isoenzymesmast cell protease 4Peptide FragmentsRNA, MessengerSerine EndopeptidasesSerine Proteinase InhibitorsSulfonamidesThiophenesThiorphanTY 51469

Identifiers

PMID23596057
PMCPMC3684843
OpenAlexW2138823068

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.